The US FDA harshly disputed Teva Pharmaceuticals USA Inc.'s claims that it is owed 180-day exclusivity for its generic version of Allergan PLC's dry eye treatment Restasis (cyclosporine), saying the company may have forfeited such rights by the time the agency approves its application.
Seeking a six-month head-start over its competitors, Teva "insists that it has 'earned' the 'reward' of '180-days of marketing exclusivity'"...







